April 28, 2020 - "Resilient business driving continued growth in challenging times"
JULY 16 2020 - In Q2, the focus was to prepare for an accelerated launch of the digital offering and the pipeline advanced as OX125 showed strong study results. According to expectations, ZUBSOLV® volume declined YoY, due to the changed position at United Health Group. In parallel, ZUBSOLV® continued to show strong profit and cash contribution, which partially compensated for the increased investments in DTx and RnD.
JULY 2 2020 - Today the company announces the US launch of its scientifically proven digital therapies deprexis® and vorvida® has been initiated. The decision to accelerate the launch of the digital offering, also incl. OXD01, is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent FDA “Enforcement Policy” providing a fast pathway to market. The accelerated launch will increase investments and OPEX FY 2020 expects to be in the range of SEK 780-800 m.
JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.
Q2–BUILDING FOR FUTURE GROWTH-Preparation for accelerated DTx launch and pipeline progress-As expected, lead produ… https://t.co/Sf9sdgfUs1
As earlier communicated the Q2 Interim Report will be out tomorrow at 8 am CET. At 3 pm CET investors, analysts & m… https://t.co/DKBqBog9il